Abstract: In this study, we have firstly investigated the feasibility of rhamnolipids as targeting ligands to develop drug delivery systems for active targeting of pancreatic cancer. Rhamnolipid-modified liposomes (RhaL-Lip) were prepared by a thin film hydration method, and were evaluated preliminarily for RhaL-Lip physicochemical properties, in vitro release characteristics, ex/in vivo targeting, and in vitro pharmacodynamics. RhaL-Lip exhibited excellent targeting ability of human pancreatic cancer (BxPC-3) cells and enhanced anti-tumor effects. On this basis, the natural structural analogue of rhamnolipid, Polyphyllin Ⅶ (PPVⅡ), as the targeting material and active ingredient, we explored the targeting and anti-tumor activity of Polyphyllin Ⅶ modified liposomes (PPVⅡ-Lip). The results showed that PPVⅡ-Lip has a homogeneous particle size and has a more robust targeting ability for solid tumor in vivo, which can achieve more enrichment at the tumor site. Compared with gemcitabine, the first-line chemotherapy drug for pancreatic cancer, PPVⅡ-Lip showed a stronger inhibitory effect. In conclusion, this targeted drug delivery strategy is expected to provide beneficial ideas for drug delivery studies in targeted therapy for pancreatic cancer. Animal experiments were conducted with approval from the Animal Ethics Committee of southwest university (approval number: IACUC-20210130-2).